ANI Pharmaceuticals CEO Arthur Przybyl's 2019 pay jumps 39% to $5.8M
ANI Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 23, 2020
ANI Pharmaceuticals reported fiscal year 2019 executive compensation information on April 23, 2020.
In 2019, four executives at ANI Pharmaceuticals received on average a compensation package of $2.9M, a 43% increase compared to previous year.
Average pay of disclosed executives at ANI Pharmaceuticals
Arthur S. Przybyl, Chief Executive Officer, received $5.8M in total, which increased by 39% compared to 2018. 43% of Przybyl's compensation, or $2.5M, was in stock awards. Przybyl also received $703K in non-equity incentive plan, $1.8M in option awards, $777K in salary, as well as $34K in other compensation.
For fiscal year 2019, the median employee pay was $46,642 at ANI Pharmaceuticals. Therefore, the ratio of Arthur S. Przybyl's pay to the median employee pay was 125 to one.
Robert Schrepfer, Senior Vice President, New Business Development and Specialty Sales, received a compensation package of $2.2M, which increased by 50% compared to previous year. 38% of the compensation package, or $827K, was in stock awards.
Stephen P. Carey, Chief Financial Officer, earned $2.2M in 2019, a 50% increase compared to previous year.
James G. Marken, Senior Vice President, Operations and Product Development, received $1.4M in 2019, which increases by 39% compared to 2018.
Related executives
Arthur Przybyl
ANI Pharmaceuticals
Chief Executive Officer
Stephen Carey
ANI Pharmaceuticals
Chief Financial Officer
James Marken
ANI Pharmaceuticals
Senior Vice President, Operations and Product Development
Robert Schrepfer
ANI Pharmaceuticals
Former Senior Vice President, New Business Development and Specialty Sales
You may also like
Source: SEC filing on April 23, 2020.